Estimates Revisions Monopar Therapeutics Inc.
Stocks
MNPR
US61023L2079
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 110.41 USD | -3.91% |
|
-7.40% | +69.08% |
| 08-13 | Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald | MT |
| 08-13 | Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- MNPR Stock
- Consensus Monopar Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
